Safe Harbor Statement

Transcription

1 1

2 Safe Harbor Statement This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forwardlooking statements involve risk and uncertainty. Forward-looking statements represent the company's judgment regarding future events, and are based on currently available information. Consequently the company cannot guarantee their accuracy and their completeness, and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of. For additional information concerning these and other important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the Autorité des Marchés Financiers.

3 3

4 3 Divisions Serving 3 Types of Customers 4

5 Important Information 5

6 3 Divisions Serving 3 Types of Customers 6

7 Definitive Purchase Agreement Executed 7

8 Next Steps on IMS Health Transaction 8

9 IMS Health Transaction: FAQ 9

10 The New Cegedim 10

11 Cegedim Will Remain on Attractive Markets 11

12 Cegedim Strengths 12

13 Financial Situation

14 Key Take Aways 14

15 Revenue Evolution 15

16 Currency Impact and Business Seasonality 16

17 CRM & Strategic Data Revenue Significant currency negative impact Positive Impact from: Emerging countries Compliance activities OneKey database-related products in all geographical region The market research activity experienced growth over the first 9 months 17

18 Healthcare Professionals Revenue As announced, increase in Q3 revenue was mainly due to: A less demanding comparison level for UK doctors software Robust growth in France in products for doctors Continued positive momentum at software for pharmacists activity in France 18

19 Insurance & Services Revenue Revenue increase mainly due to double digit growth at Third-party payer flow management Outsources payroll and HR management Electronic and automated invoicing activities Partially offset by weakness at Cegedim Global Payment caused by the transition from a perpetual license model to a SaaS offering 19

20 GERS Activities & Reconciliation Revenue Continuing growth of the sales statistics business activity 20

21 2014 Outlook 21

22 Our IR App is now available 22

23 Next Events 23

24 Appendix

25 Revenue & Organic Growth Calculation Q CRM & Strategic Data Healthcare Professionals Insurance & Services GERS Activities & Reconciliation Q Revenue a 100,193 66,016 37,617 7, ,014 Impact of disposals Q Revenue before impact of disposals 100,193 66,016 37,617 7, ,014 Currency impact (686) 1, Q Revenue at 2014 exchange rate b 99,507 67,128 37,618 7, ,445 Q Revenue before impact of acquisitions c 99,780 68,097 38,445 7, ,606 Revenue from acquisitions Q Revenue 99,780 68,411 38,445 7, ,920 Organic growth (c-b)/a 0.3% 1.5% 2.2% 1.3% 1.0% Group 9M-2014 CRM & Strategic Data Healthcare Professionals Insurance & Services GERS Activities & Reconciliation 9M 2013 Revenue a 298, , ,243 Impact of disposals M 2013 Revenue before impact of disposals 298, , ,659 21, ,243 Currency impact (7,017) 2,024 1 (20) (5,012) 9M 2013 Revenue at 2014 exchange rate b 291, , ,660 21, ,231 9M 2014 Revenue before impact of acquisitions c 294, , ,426 21, ,671 Revenue from acquisitions M 2014 Revenue 294, , ,426 21, ,649 Organic growth (c-b)/a 0.9% (3.0)% 1.5% +1.9% (0.2)% Group 25

26 Revenue Evolution per Division 26

27 First Half Key 2014 Takeaways 27

28 First Half 2014 Key Figures 28

29 Solid Financial Structure 29

30 RCF Covenant Calculation at June 30, 2014 Senior Net Debt in thousands June 30, 2014 Consolidated total debt (A) 539,849 Employee profit sharing plan (B) 9,109 Subordinated Shareholder Loans (C) 45,094 Total active cash (D) 79,834 Senior Net Debt (A-B-C-D) 405,812 Interest In thousands H H Relevant Period Interest under the total consolidated debt (A) 18,252 26,318 44,57 Other Interest (B) 1,606 1,923 3,529 Interest on shareholder loan (C) 1,241 1,189 2,43 Interest on the total consolidated cash balance of the Group (D) Total interest on Net Debt for the Relevant Period (A+B-C-D) 18,402 26,653 45,055 EBIDTA In thousands H H Relevant Period Consolidated EBIT 3,691 11,985 15,676 Impairment of goodwill 63,3 0 63,3 Consolidated Depreciations and Amortizations 34,096 32,348 66,444 Non-current income and expenses from operation IFRS 807 9,121 8,314 EBITDA for the relevant Period 100,279 53, ,733 30

31 We welcome your questions and comments Jan Eryk UMIASTOWSKI Chief Investment Officer Head of Investor Relations TEL: +33 (0)